<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
	<head>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
				<meta name="keywords" content="Adeno-associated virus,Adenosine triphosphate,Adenovirus,American Society of Gene Therapy,Antibodies,Antibody,Antibody-dependent cellular cytotoxicity,Arthritis,Atomic mass unit,Berlin,Canavan disease" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="apple-touch-icon" href="http://en.wikipedia.org/apple-touch-icon.png" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="http://www.gnu.org/copyleft/fdl.html" />
<link rel="alternate" type="application/rss+xml" title="Wikipedia RSS Feed" href="http://en.wikipedia.org/w/index.php?title=Special:Recentchanges&amp;feed=rss" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom Feed" href="http://en.wikipedia.org/w/index.php?title=Special:Recentchanges&amp;feed=atom" />
		<title>Adeno-associated virus - Wikipedia, the free encyclopedia</title>
		<style type="text/css" media="screen, projection">/*<![CDATA[*/
			@import "/skins-1.5/common/shared.css?107";
			@import "/skins-1.5/monobook/main.css?107";
		/*]]>*/</style>
		<link rel="stylesheet" type="text/css" media="print" href="/skins-1.5/common/commonPrint.css?107" />
		<!--[if lt IE 5.5000]><style type="text/css">@import "/skins-1.5/monobook/IE50Fixes.css?107";</style><![endif]-->
		<!--[if IE 5.5000]><style type="text/css">@import "/skins-1.5/monobook/IE55Fixes.css?107";</style><![endif]-->
		<!--[if IE 6]><style type="text/css">@import "/skins-1.5/monobook/IE60Fixes.css?107";</style><![endif]-->
		<!--[if IE 7]><style type="text/css">@import "/skins-1.5/monobook/IE70Fixes.css?107";</style><![endif]-->
		<!--[if lt IE 7]><script type="text/javascript" src="/skins-1.5/common/IEFixes.js?107"></script>
		<meta http-equiv="imagetoolbar" content="no" /><![endif]-->
		
		<script type= "text/javascript">/*<![CDATA[*/
var skin = "monobook";
var stylepath = "/skins-1.5";
var wgArticlePath = "/wiki/$1";
var wgScriptPath = "/w";
var wgScript = "/w/index.php";
var wgServer = "http://en.wikipedia.org";
var wgCanonicalNamespace = "";
var wgCanonicalSpecialPageName = false;
var wgNamespaceNumber = 0;
var wgPageName = "Adeno-associated_virus";
var wgTitle = "Adeno-associated virus";
var wgAction = "view";
var wgRestrictionEdit = [];
var wgRestrictionMove = [];
var wgArticleId = "1883421";
var wgIsArticle = true;
var wgUserName = "Kanzure";
var wgUserGroups = ["*", "user", "autoconfirmed", "emailconfirmed"];
var wgUserLanguage = "en";
var wgContentLanguage = "en";
var wgBreakFrames = false;
var wgCurRevisionId = "181932463";
var wgVersion = "1.12alpha";
var wgEnableAPI = true;
var wgEnableWriteAPI = false;
var wgAjaxWatch = {"watchMsg": "Watch", "unwatchMsg": "Unwatch", "watchingMsg": "Watching...", "unwatchingMsg": "Unwatching..."};
/*]]>*/</script>
                
		<script type="text/javascript" src="/skins-1.5/common/wikibits.js?107"><!-- wikibits js --></script>
		<!-- Head Scripts -->
		<script type="text/javascript" src="/skins-1.5/common/ajax.js?107"></script>
		<script type="text/javascript" src="/skins-1.5/common/ajaxwatch.js?107"></script>
		<script type="text/javascript" src="/w/index.php?title=-&amp;action=raw&amp;smaxage=0&amp;gen=js&amp;useskin=monobook"><!-- site js --></script>
		<style type="text/css">/*<![CDATA[*/
@import "/w/index.php?title=MediaWiki:Common.css&usemsgcache=yes&action=raw&ctype=text/css&smaxage=2678400";
@import "/w/index.php?title=MediaWiki:Monobook.css&usemsgcache=yes&action=raw&ctype=text/css&smaxage=2678400";
@import "/w/index.php?title=-&action=raw&gen=css&maxage=2678400&smaxage=0&ts=20080125141459";
@import "/w/index.php?title=User:Kanzure/monobook.css&action=raw&ctype=text/css";
/*]]>*/</style>
		<script type="text/javascript" src="/w/index.php?title=User:Kanzure/monobook.js&amp;action=raw&amp;ctype=text/javascript&amp;dontcountme=s"></script>
	</head>
<body class="mediawiki ns-0 ltr page-Adeno-associated_virus">
	<div id="globalWrapper">
		<div id="column-content">
	<div id="content">
		<a name="top" id="top"></a>
				<h1 class="firstHeading">Adeno-associated virus</h1>
		<div id="bodyContent">
			<h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
			<div id="contentSub"></div>
									<div id="jump-to-nav">Jump to: <a href="#column-one">navigation</a>, <a href="#searchInput">search</a></div>			<!-- start content -->
			<table class="infobox biota" style="text-align:center; padding:2.5px; width:200px;">
<tr style="text-align:center;">
<th style="background:violet;">Adeno-associated virus</th>
</tr>
<tr style="text-align:center;">
<td></td>
</tr>
<tr style="text-align:center;">
<th style="background:violet;"><a href="/wiki/Virus_classification" title="Virus classification">Virus classification</a></th>
</tr>
<tr style="text-align:center;">
<td>
<table style="margin:0 auto; text-align:left; background:transparent;" cellpadding="2">
<tr valign="top">
<td>Group:</td>
<td>Group II <small>(<a href="/wiki/SsDNA_virus" title="SsDNA virus">ssDNA</a>)</small></td>
</tr>
<tr valign="top">
<td>Family:</td>
<td><span class="family"><i><a href="/wiki/Parvoviridae" title="Parvoviridae">Parvoviridae</a></i></span><br /></td>
</tr>
<tr valign="top">
<td>Subfamily:</td>
<td><span class="subfamily"><i><a href="/w/index.php?title=Parvovirinae&amp;action=edit" class="new" title="Parvovirinae">Parvovirinae</a></i></span><br /></td>
</tr>
<tr valign="top">
<td>Genus:</td>
<td><span class="genus"><i>Dependovirus</i></span><br /></td>
</tr>
<tr valign="top">
<td>Species:</td>
<td><span style="white-space:nowrap;"><i>adeno-associated virus</i></span><br /></td>
</tr>
</table>
</td>
</tr>
</table>
<p><b>Adeno-associated virus (AAV)</b> is a small <a href="/wiki/Virus" title="Virus">virus</a> which infects humans and some other primate species. AAV is not currently known to cause <a href="/wiki/Disease" title="Disease">disease</a> and consequently the virus causes a very mild <a href="/wiki/Immune_response" title="Immune response">immune response</a>. AAV can infect both dividing and non-dividing cells and may incorporate its <a href="/wiki/Genome" title="Genome">genome</a> into that of the host cell. These features make AAV a very attractive candidate for creating viral vectors for <a href="/wiki/Gene_therapy" title="Gene therapy">gene therapy</a>.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Overview"><span class="tocnumber">1</span> <span class="toctext">Overview</span></a></li>
<li class="toclevel-1"><a href="#Gene_Therapy_Vector"><span class="tocnumber">2</span> <span class="toctext">Gene Therapy Vector</span></a>
<ul>
<li class="toclevel-2"><a href="#Advantages_and_drawbacks"><span class="tocnumber">2.1</span> <span class="toctext">Advantages and drawbacks</span></a></li>
<li class="toclevel-2"><a href="#Clinical_trials"><span class="tocnumber">2.2</span> <span class="toctext">Clinical trials</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#AAV_structure"><span class="tocnumber">3</span> <span class="toctext">AAV structure</span></a>
<ul>
<li class="toclevel-2"><a href="#AAV_genome.2C_transcriptome_and_proteome"><span class="tocnumber">3.1</span> <span class="toctext">AAV genome, transcriptome and proteome</span></a>
<ul>
<li class="toclevel-3"><a href="#ITR_sequences"><span class="tocnumber">3.1.1</span> <span class="toctext">ITR sequences</span></a></li>
<li class="toclevel-3"><a href="#rep_genes_and_Rep_proteins"><span class="tocnumber">3.1.2</span> <span class="toctext">rep genes and Rep proteins</span></a></li>
<li class="toclevel-3"><a href="#cap_genes_and_VP_proteins"><span class="tocnumber">3.1.3</span> <span class="toctext">cap genes and VP proteins</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1"><a href="#AAV_serotypes.2C_receptors_and_native_tropism"><span class="tocnumber">4</span> <span class="toctext">AAV serotypes, receptors and native tropism</span></a>
<ul>
<li class="toclevel-2"><a href="#Serotype_2"><span class="tocnumber">4.1</span> <span class="toctext">Serotype 2</span></a>
<ul>
<li class="toclevel-3"><a href="#Serotype_2_and_cancer"><span class="tocnumber">4.1.1</span> <span class="toctext">Serotype 2 and cancer</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#Other_Serotypes"><span class="tocnumber">4.2</span> <span class="toctext">Other Serotypes</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#AAV_immunology"><span class="tocnumber">5</span> <span class="toctext">AAV immunology</span></a>
<ul>
<li class="toclevel-2"><a href="#Innate"><span class="tocnumber">5.1</span> <span class="toctext">Innate</span></a></li>
<li class="toclevel-2"><a href="#Humoral"><span class="tocnumber">5.2</span> <span class="toctext">Humoral</span></a></li>
<li class="toclevel-2"><a href="#Cell-mediated"><span class="tocnumber">5.3</span> <span class="toctext">Cell-mediated</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#AAV_infection_cycle"><span class="tocnumber">6</span> <span class="toctext">AAV infection cycle</span></a></li>
<li class="toclevel-1"><a href="#Notes"><span class="tocnumber">7</span> <span class="toctext">Notes</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">8</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="Overview" id="Overview"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=1" title="Edit section: Overview">edit</a>]</span> <span class="mw-headline">Overview</span></h2>
<p><i><a href="/wiki/Dependovirus" title="Dependovirus">Dependovirus</a> adeno-associated virus</i> belongs to the <i><a href="/wiki/Parvoviridae" title="Parvoviridae">Parvoviridae</a></i>. The virus is a small (20 nm) <a href="/wiki/Replication-defective_virus" title="Replication-defective virus">replication-defective</a>, <a href="/wiki/Enveloped_virus" title="Enveloped virus">nonenveloped virus</a> of <a href="/wiki/Mammals" title="Mammals">mammals</a> (including humans), which has not been associated with any known diseases. AAV is being extensively researched as a potential vector for <a href="/wiki/Gene_therapy" title="Gene therapy">gene therapy</a><sup id="_ref-GriegerSamulski2005_0" class="reference"><a href="#_note-GriegerSamulski2005" title="">[1]</a></sup> as it possesses many advantages in this regard.</p>
<p><a name="Gene_Therapy_Vector" id="Gene_Therapy_Vector"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=2" title="Edit section: Gene Therapy Vector">edit</a>]</span> <span class="mw-headline">Gene Therapy Vector</span></h2>
<p><a name="Advantages_and_drawbacks" id="Advantages_and_drawbacks"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=3" title="Edit section: Advantages and drawbacks">edit</a>]</span> <span class="mw-headline">Advantages and drawbacks</span></h3>
<p>Wild-type AAV has attracted considerable interest from gene therapy researchers due to a number of features. Chief amongst these is the viruses' apparent lack of pathogenicity. It can also infect non-dividing cells and has the ability to stably integrate into the host cell genome at a specific site (designated AAVS1) in the human 19<sup>th</sup> <a href="/wiki/Chromosome" title="Chromosome">chromosome</a>.<sup id="_ref-SuroskyUrabe1997_0" class="reference"><a href="#_note-SuroskyUrabe1997" title="">[2]</a></sup> The feature makes it somewhat more predictable than <a href="/wiki/Retrovirus" title="Retrovirus">retroviruses</a>, which present threat of a random insertion and of mutagenesis, which is sometimes followed by development of a <a href="/wiki/Cancer" title="Cancer">cancer</a>. The AAV genome integrates most frequently into the site mentioned, while random incorporations into the genome take place with a negligible frequency. AAVs also present very low <a href="/wiki/Immunogenicity" title="Immunogenicity">immunogenicity</a>, seemingly restricted to generation of neutralizing <a href="/wiki/Antibodies" title="Antibodies">antibodies</a>, while they induce no clearly-defined <a href="/wiki/Antibody-dependent_cellular_cytotoxicity" title="Antibody-dependent cellular cytotoxicity">cytotoxic response</a>.<sup id="_ref-ChirmulePropert1999_0" class="reference"><a href="#_note-ChirmulePropert1999" title="">[3]</a></sup><sup id="_ref-HernandezWang1999_0" class="reference"><a href="#_note-HernandezWang1999" title="">[4]</a></sup><sup id="_ref-PonnazhaganMukherjee1997_0" class="reference"><a href="#_note-PonnazhaganMukherjee1997" title="">[5]</a></sup> This feature, along with the ability to infect quiescent cells present their dominance over <a href="/wiki/Adenovirus" title="Adenovirus">adenoviruses</a> as vectors for the human <a href="/wiki/Gene_therapy" title="Gene therapy">gene therapy</a>.</p>
<p>Use of the virus does present some disadvantages. The cloning capacity of the vector is relatively limited and most therapeutic genes require the complete replacement of the virus's 4.8 kilobase genome. It is accordingly unclear if the site-specific integration can be preserved in a usable vector since it appears to be partially dependent on products of the Rep open reading frame. The humoral immunity instigated by infection with the wild type is thought to be a very common event. The associated neutralising activity limits the usefulness of the most commonly used serotype AAV2 in certain applications.</p>
<p><a name="Clinical_trials" id="Clinical_trials"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=4" title="Edit section: Clinical trials">edit</a>]</span> <span class="mw-headline">Clinical trials</span></h3>
<p>To date, AAV vectors have been used for first- and second-phase clinical trials for treatment of <a href="/wiki/Cystic_fibrosis" title="Cystic fibrosis">cystic fibrosis</a> and first-phase trials for <a href="/wiki/Hemophilia" title="Hemophilia">hemophilia</a>. Promising results have been obtained from phase I trials for <a href="/wiki/Parkinson%27s_disease" title="Parkinson's disease">Parkinson's disease</a>, showing good tolerance of an AAV2 vector in the central nervous system. Other trials have begun, concerning AAV safety for treatment of <a href="/wiki/Canavan_disease" title="Canavan disease">Canavan disease</a>, <a href="/wiki/Muscular_dystrophy" title="Muscular dystrophy">muscular dystrophy</a> and late infantile <a href="/wiki/Neuronal_ceroid_lipofuscinosis" title="Neuronal ceroid lipofuscinosis">neuronal ceroid lipofuscinosis</a>.</p>
<table class="wikitable" style="text-align:center">
<caption>Selection of Clinical Trials using AAV-Based Vectors<sup id="_ref-Carter2005_0" class="reference"><a href="#_note-Carter2005" title="">[6]</a></sup></caption>
<tr>
<td>Indication</td>
<td>Gene</td>
<td>Route of administration</td>
<td>Phase</td>
<td>Subject number</td>
<td>Status</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
<td><a href="/wiki/Cystic_fibrosis_transmembrane_conductance_regulator" title="Cystic fibrosis transmembrane conductance regulator">CFTR</a></td>
<td>Lung, via aerosol</td>
<td>I</td>
<td>12</td>
<td>Complete</td>
</tr>
<tr>
<td></td>
<td>CFTR</td>
<td>Lung, via aerosol</td>
<td>II</td>
<td>38</td>
<td>Complete</td>
</tr>
<tr>
<td></td>
<td>CFTR</td>
<td>Lung, via aerosol</td>
<td>II</td>
<td>100</td>
<td>Complete</td>
</tr>
<tr>
<td>Hemophilia B</td>
<td><a href="/wiki/Factor_IX" title="Factor IX">FIX</a></td>
<td>Intramuscular</td>
<td>I</td>
<td>9</td>
<td>Complete</td>
</tr>
<tr>
<td></td>
<td>FIX</td>
<td>Hepatic artery</td>
<td>I</td>
<td>6</td>
<td>Ended</td>
</tr>
<tr>
<td><a href="/wiki/Arthritis" title="Arthritis">Arthritis</a></td>
<td><a href="/wiki/Tumor_necrosis_factor-alpha" title="Tumor necrosis factor-alpha">TNFR:Fc</a></td>
<td>Intraarticular</td>
<td>I</td>
<td>1</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Hereditary emphysema</td>
<td>AAT</td>
<td>Intramuscular</td>
<td>I</td>
<td>12</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Muscular dystrophy</td>
<td>Sarcoglycan</td>
<td>Intramuscular</td>
<td>I</td>
<td>10</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Parkinson's</td>
<td>GAD65, GAD67</td>
<td>Intracranial</td>
<td>I</td>
<td>12</td>
<td>Complete<sup id="_ref-KaplittFeigin2007_0" class="reference"><a href="#_note-KaplittFeigin2007" title="">[7]</a></sup></td>
</tr>
<tr>
<td>Canavan's</td>
<td>AAC</td>
<td>Intracranial</td>
<td>I</td>
<td>21</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Batten's</td>
<td>CLN2</td>
<td>Intracranial</td>
<td>I</td>
<td>10</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Alzheimer's</td>
<td>NGF</td>
<td>Intracranial</td>
<td>I</td>
<td>6</td>
<td>Ongoing</td>
</tr>
</table>
<p>Trials for the treatment of <a href="/wiki/Prostate_cancer" title="Prostate cancer">prostate cancer</a> have reached phase III<sup id="_ref-Carter2005_1" class="reference"><a href="#_note-Carter2005" title="">[6]</a></sup>, however these ex vivo studies do not involve direct administration of AAV to patients.</p>
<p><a name="AAV_structure" id="AAV_structure"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=5" title="Edit section: AAV structure">edit</a>]</span> <span class="mw-headline">AAV structure</span></h2>
<table style="" class="metadata plainlinks ambox ambox-notice">
<tr>
<td class="ambox-image">
<div style="width:52px;"><a href="/wiki/Image:Wiki_letter_w.svg" class="image" title="Wiki letter w.svg"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/6/6c/Wiki_letter_w.svg/36px-Wiki_letter_w.svg.png" width="36" height="36" border="0" /></a></div>
</td>
<td class="ambox-text"><i>Please help <a href="http://en.wikipedia.org/w/index.php?title=Adeno-associated_virus&amp;action=edit" class="external text" title="http://en.wikipedia.org/w/index.php?title=Adeno-associated_virus&amp;action=edit" rel="nofollow">improve this article</a> by expanding this section.</i><br />
<small>See <a href="/wiki/Talk:Adeno-associated_virus" title="Talk:Adeno-associated virus">talk page</a> for details. Please remove this message once the section has been expanded.</small></td>
</tr>
</table>
<p><a name="AAV_genome.2C_transcriptome_and_proteome" id="AAV_genome.2C_transcriptome_and_proteome"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=6" title="Edit section: AAV genome, transcriptome and proteome">edit</a>]</span> <span class="mw-headline">AAV genome, transcriptome and proteome</span></h3>
<p>The AAV genome is built of single-stranded deoxyribonucleic acid (ss<a href="/wiki/DNA" title="DNA">DNA</a>), either positive- or negative-sensed, which is about 4.7 kilobase long. The genome comprises inverted terminal repeats (ITRs) at both ends of the DNA strand, and two <a href="/wiki/Open_reading_frame" title="Open reading frame">open reading frames</a> (ORFs): <i>rep</i> and <i>cap</i>. The former is composed of four overlapping genes encoding Rep proteins required for the AAV life cycle, and the latter contains overlapping nucleotide sequences of <a href="/wiki/Capsid" title="Capsid">capsid</a> proteins: VP1, VP2 and VP3, which interact together to form a capsid of an icosahedral symmetry.<sup id="_ref-Carter2000_0" class="reference"><a href="#_note-Carter2000" title="">[8]</a></sup></p>
<p><a name="ITR_sequences" id="ITR_sequences"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=7" title="Edit section: ITR sequences">edit</a>]</span> <span class="mw-headline">ITR sequences</span></h4>
<p>The Inverted Terminal Repeat (ITR) sequences comprise 145 bases each. They were named so because of their symmetry, which was shown to be required for efficient multiplication of the AAV genome.<sup id="_ref-BohenzkyLefebvreBerns1988_0" class="reference"><a href="#_note-BohenzkyLefebvreBerns1988" title="">[9]</a></sup> Another property of these sequences is their ability to form a <a href="/wiki/Stem-loop" title="Stem-loop">hairpin</a>, which contributes to so-called self-priming that allows <a href="/wiki/Primase" title="Primase">primase</a>-independent synthesis of the second DNA strand. The ITRs were also shown to be required for both integration of the AAV DNA into the host cell genome (19<sup>th</sup> chromosome in humans) and rescue from it,<sup id="_ref-WangPonnazhagan1995_0" class="reference"><a href="#_note-WangPonnazhagan1995" title="">[10]</a></sup><sup id="_ref-WeitzmanKyostio1994_0" class="reference"><a href="#_note-WeitzmanKyostio1994" title="">[11]</a></sup> as well as for efficient encapsidation of the AAV DNA combined with generation of a fully-assembled, <a href="/wiki/Deoxyribonuclease" title="Deoxyribonuclease">deoxyribonuclease</a>-resistant AAV particles.<sup id="_ref-ZhouMuzyczka1998_0" class="reference"><a href="#_note-ZhouMuzyczka1998" title="">[12]</a></sup></p>
<p>With regard to gene therapy, ITRs seem to be the only sequences required <i><a href="/wiki/Cis-acting" title="Cis-acting">in cis</a></i> next to the therapeutic gene: structural (<i>cap</i>) and packaging (<i>rep</i>) genes can be delivered <i><a href="/wiki/Trans-acting_factors" title="Trans-acting factors">in trans</a></i>. With this assumption many methods were established for efficient production of recombinant AAV (rAAV) vectors containing a <a href="/wiki/Reporter_gene" title="Reporter gene">reporter</a> or therapeutic gene. However, it was also published that the ITRs are not the only elements required <i>in cis</i> for the effective replication and encapsidation. A few research groups have identified a sequence designated <i>cis-acting Rep-dependent element</i> (CARE) inside the coding sequence of the <i>rep</i> gene. CARE was shown to augment the replication and encapsidation when present <i>in cis</i>.<sup id="_ref-NonyTessier2001_0" class="reference"><a href="#_note-NonyTessier2001" title="">[13]</a></sup><sup id="_ref-0" class="reference"><a href="#_note-0" title="">[14]</a></sup><sup id="_ref-PhilpottGiraud2002_0" class="reference"><a href="#_note-PhilpottGiraud2002" title="">[15]</a></sup><sup id="_ref-1" class="reference"><a href="#_note-1" title="">[16]</a></sup></p>
<p><a name="rep_genes_and_Rep_proteins" id="rep_genes_and_Rep_proteins"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=8" title="Edit section: rep genes and Rep proteins">edit</a>]</span> <span class="mw-headline"><i>rep</i> genes and Rep proteins</span></h4>
<p>On the "left side" of the genome there are two <a href="/wiki/Promoter" title="Promoter">promoters</a> called p5 and p19, from which two overlapping messenger ribonucleic acids (<a href="/wiki/MRNA" title="MRNA">mRNAs</a>) of different length can be produced. Each of these contains an <a href="/wiki/Intron" title="Intron">intron</a> which can be either <a href="/wiki/Splicing_%28genetics%29" title="Splicing (genetics)">spliced</a> out or not. Given these possibilities, four various mRNAs, and consequently four various Rep proteins with overlapping sequence can be synthesized. Their names depict their sizes in <a href="/wiki/Atomic_mass_unit" title="Atomic mass unit">kilodaltons</a> (kDa): Rep78, Rep68, Rep52 and Rep40.<sup id="_ref-KyostioOwens1994_0" class="reference"><a href="#_note-KyostioOwens1994" title="">[17]</a></sup> Rep78 and 68 can specifically bind the <a href="/wiki/Hairpin" title="Hairpin">hairpin</a> formed by the ITR in the self-priming act and cleave at a specific region, designated terminal resolution site, within the hairpin. They were also shown to be necessary for the AAVS1-specific integration of the AAV genome. All four Rep proteins were shown to bind <a href="/wiki/Adenosine_triphosphate" title="Adenosine triphosphate">ATP</a> and to possess <a href="/wiki/Helicase" title="Helicase">helicase</a> activity. It was also shown that they upregulate the transcription from the p40 promoter (mentioned below), but downregulate both p5 and p19 promoters.<sup id="_ref-ImMuzyczka1990_0" class="reference"><a href="#_note-ImMuzyczka1990" title="">[18]</a></sup><sup id="_ref-ImMuzyczka1992_0" class="reference"><a href="#_note-ImMuzyczka1992" title="">[19]</a></sup><sup id="_ref-KyostioOwens1994_1" class="reference"><a href="#_note-KyostioOwens1994" title="">[17]</a></sup><sup id="_ref-Samulski2003_0" class="reference"><a href="#_note-Samulski2003" title="">[20]</a></sup><sup id="_ref-TrempeCarter1988a_0" class="reference"><a href="#_note-TrempeCarter1988a" title="">[21]</a></sup><sup id="_ref-WeitzmanKyostio1994_1" class="reference"><a href="#_note-WeitzmanKyostio1994" title="">[11]</a></sup></p>
<p><a name="cap_genes_and_VP_proteins" id="cap_genes_and_VP_proteins"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=9" title="Edit section: cap genes and VP proteins">edit</a>]</span> <span class="mw-headline"><i>cap</i> genes and VP proteins</span></h4>
<p>The right side of a positive-sensed AAV genome encodes overlapping sequences of three capsid proteins, VP1, VP2 and VP3, which start from one promoter, designated p40. The molecular weights of these proteins are 87, 72 and 62 kiloDaltons, respectively.<sup id="_ref-JayLaughlin1981_0" class="reference"><a href="#_note-JayLaughlin1981" title="">[22]</a></sup> All three of them are translated from one mRNA. After this mRNA is synthesized, it can be <a href="/wiki/Splicing_%28genetics%29" title="Splicing (genetics)">spliced</a> in two different manners: either longer or shorter <a href="/wiki/Intron" title="Intron">intron</a> can be excised, which results in formation of two pools of mRNAs: 2.3 kb-, and 2.6 kb-long. Usually, especially in the presence of <a href="/wiki/Adenovirus" title="Adenovirus">adenovirus</a>, the longer intron is preferred, so the 2.3-kb-long mRNA represents so-called major splice. In this form the first <a href="/wiki/Start_codon" title="Start codon">AUG codon</a>, from which the synthesis of VP1 protein starts, is cut out, resulting in a reduced overall level of VP1 protein synthesis. The first AUG codon, which remains in the major splice, is the initiation codon for VP3 protein. However, upstream of that codon in the same open reading frame lies the ACG sequence, which endcodes threonine, but is surrounded by the optimal <a href="/wiki/Kozak_consensus_sequence" title="Kozak consensus sequence">Kozak context</a>, that contributes to a low level of synthesis of VP2 protein, which is actually VP3 protein with additional N terminal residues, as is VP1.<sup id="_ref-BecerraRose1985_0" class="reference"><a href="#_note-BecerraRose1985" title="">[23]</a></sup><sup id="_ref-CassinottiWeitz1988_0" class="reference"><a href="#_note-CassinottiWeitz1988" title="">[24]</a></sup><sup id="_ref-MuralidharBecerra1994_0" class="reference"><a href="#_note-MuralidharBecerra1994" title="">[25]</a></sup><sup id="_ref-TrempeCarter1988b_0" class="reference"><a href="#_note-TrempeCarter1988b" title="">[26]</a></sup></p>
<p>Since the bigger intron is preferred to be spliced out, and since in the major splice the ACG codon is a much weaker <a href="/wiki/Translation" title="Translation">translation</a> initiation signal, the ratio at which the AAV structural proteins are synthesized <i>in vivo</i> is about 1:1:20, which is the same as in the mature virus particle.<sup id="_ref-RabinowitzSamulski2000_0" class="reference"><a href="#_note-RabinowitzSamulski2000" title="">[27]</a></sup> The unique fragment at the N terminus of VP1 protein was shown to possess the <a href="/wiki/Phospholipase" title="Phospholipase">phospholipase</a> A2 (PLA2) activity, which is probably required for the releasing of AAV particles from late <a href="/wiki/Endosome" title="Endosome">endosomes</a>.<sup id="_ref-GirodWobus2002_0" class="reference"><a href="#_note-GirodWobus2002" title="">[28]</a></sup> Muralidhar <i>et al.</i> reported that VP2 and VP3 are crucial for correct virion assembly.<sup id="_ref-MuralidharBecerra1994_1" class="reference"><a href="#_note-MuralidharBecerra1994" title="">[25]</a></sup> More recently, however, Warrington <i>et al</i> showed VP2 to be unnecessary for the complete virus particle formation and an efficient infectivity, and also presented that VP2 can tolerate large insertions in its N terminus, while VP1 can not, probably because of the PLA2 domain presence.<sup id="_ref-WarringtonGorbatyuk1994_0" class="reference"><a href="#_note-WarringtonGorbatyuk1994" title="">[29]</a></sup></p>
<p>The <a href="/wiki/Crystal_structure" title="Crystal structure">crystal structure</a> of the VP3 protein was determined by Xie, Bue, <i>et al</i>.<sup id="_ref-XieBu2002_0" class="reference"><a href="#_note-XieBu2002" title="">[30]</a></sup></p>
<p><a name="AAV_serotypes.2C_receptors_and_native_tropism" id="AAV_serotypes.2C_receptors_and_native_tropism"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=10" title="Edit section: AAV serotypes, receptors and native tropism">edit</a>]</span> <span class="mw-headline">AAV serotypes, receptors and native tropism</span></h2>
<p>As of 2006 there have been 11 AAV <a href="/wiki/Serotype" title="Serotype">serotypes</a> described, the 11<sup>th</sup> in 2004.<sup id="_ref-MoriWang2004_0" class="reference"><a href="#_note-MoriWang2004" title="">[31]</a></sup> All of the known serotypes can infect cells from multiple diverse tissue types. Tissue specificity is determined by the capsid serotype and pseudotyping of AAV vectors to alter their tropism range will likely be important to their use in therapy.</p>
<p><a name="Serotype_2" id="Serotype_2"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=11" title="Edit section: Serotype 2">edit</a>]</span> <span class="mw-headline">Serotype 2</span></h3>
<p>Serotype 2 (AAV2) has been the most extensively examined so far.<sup id="_ref-BartlettSamulski1998_0" class="reference"><a href="#_note-BartlettSamulski1998" title="">[32]</a></sup><sup id="_ref-FischerBeck2003_0" class="reference"><a href="#_note-FischerBeck2003" title="">[33]</a></sup><sup id="_ref-NicklinBuening2001_0" class="reference"><a href="#_note-NicklinBuening2001" title="">[34]</a></sup><sup id="_ref-RabinowitzXiao1999_0" class="reference"><a href="#_note-RabinowitzXiao1999" title="">[35]</a></sup><sup id="_ref-ShiBartlett2003_0" class="reference"><a href="#_note-ShiBartlett2003" title="">[36]</a></sup><sup id="_ref-WuXiao2000_0" class="reference"><a href="#_note-WuXiao2000" title="">[37]</a></sup> AAV2 presents natural tropism towards e.g. <a href="/wiki/Skeletal_muscle" title="Skeletal muscle">skeletal muscles</a>,<sup id="_ref-MannoChew2003_0" class="reference"><a href="#_note-MannoChew2003" title="">[38]</a></sup> <a href="/wiki/Neuron" title="Neuron">neurons</a>,<sup id="_ref-BartlettSamulski1998_1" class="reference"><a href="#_note-BartlettSamulski1998" title="">[32]</a></sup> <a href="/wiki/Vascular_smooth_muscle" title="Vascular smooth muscle">vascular smooth muscle</a> cells<sup id="_ref-RichterIwata2000_0" class="reference"><a href="#_note-RichterIwata2000" title="">[39]</a></sup> and <a href="/wiki/Hepatocyte" title="Hepatocyte">hepatocytes</a>.<sup id="_ref-KoeberlAlexander1997_0" class="reference"><a href="#_note-KoeberlAlexander1997" title="">[40]</a></sup></p>
<p>Three cell receptors haver been described for AAV2: <a href="/wiki/Heparan_sulfate#Proteoglycans" title="Heparan sulfate">heparan sulfate proteoglican</a> (HSPG), a<sub>V</sub>β<sub>5</sub> <a href="/wiki/Integrin" title="Integrin">integrin</a> and <a href="/wiki/Fibroblast_growth_factor" title="Fibroblast growth factor">fibroblast growth factor</a> receptor 1 (FGFR-1). The first functions as a primary receptor, while the latter two have a co-receptor activity and enable AAV to enter the cell by receptor-mediated <a href="/wiki/Endocytosis" title="Endocytosis">endocytosis</a>.<sup id="_ref-QinqMah1999_0" class="reference"><a href="#_note-QinqMah1999" title="">[41]</a></sup><sup id="_ref-SummerfordSamulski1998_0" class="reference"><a href="#_note-SummerfordSamulski1998" title="">[42]</a></sup><sup id="_ref-SummerfordBartlett1999_0" class="reference"><a href="#_note-SummerfordBartlett1999" title="">[43]</a></sup>) These study results have been disputed by Qiu, Handa, <i>et al</i>.<sup id="_ref-QiuHanda2001_0" class="reference"><a href="#_note-QiuHanda2001" title="">[44]</a></sup> HSPG functions as the primary receptor, though its abundance in the <a href="/wiki/Extracellular_matrix" title="Extracellular matrix">extracellular matrix</a> can scavenge AAV particles and impair the infection efficiency.<sup id="_ref-PajusolaGruchala2002_0" class="reference"><a href="#_note-PajusolaGruchala2002" title="">[45]</a></sup></p>
<p><a name="Serotype_2_and_cancer" id="Serotype_2_and_cancer"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=12" title="Edit section: Serotype 2 and cancer">edit</a>]</span> <span class="mw-headline">Serotype 2 and cancer</span></h4>
<p>Studies have shown that serotype 2 of the virus (AAV-2) apparently kills cancer cells without harming healthy ones. "Our results suggest that adeno-associated virus type 2, which infects the majority of the population but has no known ill effects, kills multiple types of cancer cells yet has no effect on healthy cells," said <a href="http://www.fred.psu.edu/ds/retrieve/fred/investigator/cmm10" class="external text" title="http://www.fred.psu.edu/ds/retrieve/fred/investigator/cmm10" rel="nofollow">Craig Meyers</a>, a professor of <a href="/wiki/Immunology" title="Immunology">immunology</a> and <a href="/wiki/Microbiology" title="Microbiology">microbiology</a> at the <a href="/wiki/Penn_State" title="Penn State">Penn State</a> College of Medicine in <a href="/wiki/Pennsylvania" title="Pennsylvania">Pennsylvania</a>.<sup id="_ref-Cnn2005_0" class="reference"><a href="#_note-Cnn2005" title="">[46]</a></sup> This could lead to a new anti-cancer agent.</p>
<p><a name="Other_Serotypes" id="Other_Serotypes"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=13" title="Edit section: Other Serotypes">edit</a>]</span> <span class="mw-headline">Other Serotypes</span></h3>
<p>Although AAV2 is the most popular serotype in various AAV-based research, it has been shown that other serotypes can be more effective as gene delivery vectors. For instance AAV6 appears much better in infecting airway epithelial cells, AAV7 presents very high transduction rate of murine skeletal muscle cells (similarly to AAV1 and AAV5), AAV8 is superb in transducing hepatocytes<sup id="_ref-GaoAlvira2002_0" class="reference"><a href="#_note-GaoAlvira2002" title="">[47]</a></sup><sup id="_ref-HalbertAllen2001_0" class="reference"><a href="#_note-HalbertAllen2001" title="">[48]</a></sup><sup id="_ref-RabinowitzBowles2004_0" class="reference"><a href="#_note-RabinowitzBowles2004" title="">[49]</a></sup> and AAV1 and 5 were shown to be very efficient in gene delivery to vascular endothelial cells.<sup id="_ref-ChenKapturczak2005_0" class="reference"><a href="#_note-ChenKapturczak2005" title="">[50]</a></sup> AAV6, a hybrid of AAV1 and AAV2,<sup id="_ref-RabinowitzBowles2004_1" class="reference"><a href="#_note-RabinowitzBowles2004" title="">[49]</a></sup> also shows lower immunogenicity than AAV2.<sup id="_ref-HalbertAllen2001_1" class="reference"><a href="#_note-HalbertAllen2001" title="">[48]</a></sup></p>
<p>Serotypes can differ with the respect to the receptors they are bound to. For example AAV4 and AAV5 transduction can be inhibited by soluble <a href="/wiki/Sialic_acid" title="Sialic acid">sialic acids</a> (of different form for each of these serotypes),<sup id="_ref-KaludovBrown2001_0" class="reference"><a href="#_note-KaludovBrown2001" title="">[51]</a></sup> and AAV5 was shown to enter cells via the <a href="/wiki/Platelet-derived_growth_factor" title="Platelet-derived growth factor">platelet-derived growth factor</a> receptor.<sup id="_ref-DiPasqualeDavidson2003_0" class="reference"><a href="#_note-DiPasqualeDavidson2003" title="">[52]</a></sup></p>
<p><a name="AAV_immunology" id="AAV_immunology"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=14" title="Edit section: AAV immunology">edit</a>]</span> <span class="mw-headline">AAV immunology</span></h2>
<p>AAV is of particular interest to gene therapists due to its apparent limited capacity to induce immune responses in humans, a factor which should positively influence vector transduction efficiency while reducing the risk of any immune-associated <a href="/wiki/Pathology" title="Pathology">pathology</a>.</p>
<p><a name="Innate" id="Innate"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=15" title="Edit section: Innate">edit</a>]</span> <span class="mw-headline">Innate</span></h3>
<p>The <a href="/wiki/Innate_immune_system" title="Innate immune system">innate</a> immune response to the AAV vectors has been characterised in animal models. Intravenous administration in mice causes transient production of pro-inflammatory <a href="/wiki/Cytokine" title="Cytokine">cytokines</a> and some infiltration of <a href="/wiki/Neutrophil" title="Neutrophil">neutrophils</a> and other <a href="/wiki/Leukocyte" title="Leukocyte">leukocytes</a> into the liver, which seems to sequester a large percentage of the injected viral particles. Both soluble factor levels and cell infiltration appear to return to baseline within six hours. By contrast, more aggressive viruses produce innate responses lasting 24 hours or longer.<sup id="_ref-ZaissLiu2002_0" class="reference"><a href="#_note-ZaissLiu2002" title="">[53]</a></sup></p>
<p><a name="Humoral" id="Humoral"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=16" title="Edit section: Humoral">edit</a>]</span> <span class="mw-headline">Humoral</span></h3>
<p>The virus is known to instigate robust <a href="/wiki/Humoral_immune_system" title="Humoral immune system">humoral</a> immunity in animal models and in the human population where up to 80% of individuals are thought to be <a href="/wiki/Seropositivity" title="Seropositivity">seropositive</a> for AAV2. <a href="/wiki/Antibody" title="Antibody">Antibodies</a> are known to be neutralising and do impact on vector transduction efficiency via some routes of administration. As well as persistent AAV specific antibody levels, it appears from both prime-boost studies in animals and from clinical trials that the B-cell memory is also strong.<sup id="_ref-ZaissMuruve2005_0" class="reference"><a href="#_note-ZaissMuruve2005" title="">[54]</a></sup></p>
<p><a name="Cell-mediated" id="Cell-mediated"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=17" title="Edit section: Cell-mediated">edit</a>]</span> <span class="mw-headline">Cell-mediated</span></h3>
<p>The <a href="/wiki/Cell-mediated_immunity" title="Cell-mediated immunity">cell-mediated</a> response to the virus and to vectors is poorly characterised and has been largely ignored in the literature as recently as 2005.<sup id="_ref-ZaissMuruve2005_1" class="reference"><a href="#_note-ZaissMuruve2005" title="">[54]</a></sup> Clinical trials using an AAV2-based vector to treat haemophilia B seem to indicate that targeted destruction of transduced cells may be occurring.<sup id="_ref-MannosHigh2006_0" class="reference"><a href="#_note-MannosHigh2006" title="">[55]</a></sup> Combined with data that shows that CD8+ T-cells can recognise elements of the AAV capsid in vitro<sup id="_ref-SabatinoHigh2005_0" class="reference"><a href="#_note-SabatinoHigh2005" title="">[56]</a></sup>, it appears that there may be a cytotoxic T lymphocyte response to AAV vectors. However, the data is incomplete as the role of T-helper cells and evidence of targeted cytoxicity has not been fully explored.</p>
<p><a name="AAV_infection_cycle" id="AAV_infection_cycle"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=18" title="Edit section: AAV infection cycle">edit</a>]</span> <span class="mw-headline">AAV infection cycle</span></h2>
<p>There are several steps in the AAV infection cycle, from infecting a cell to producing new infectious particles:</p>
<ol>
<li>attachment to the <a href="/wiki/Cell_membrane" title="Cell membrane">cell membrane</a></li>
<li><a href="/wiki/Endocytosis" title="Endocytosis">endocytosis</a></li>
<li>endosomal trafficking</li>
<li>escape from the late <a href="/wiki/Endosome" title="Endosome">endosome</a> or <a href="/wiki/Lysosome" title="Lysosome">lysosome</a></li>
<li>translocation to the <a href="/wiki/Cell_nucleus" title="Cell nucleus">nucleus</a></li>
<li>formation of double-stranded DNA replicative form of the AAV genome</li>
<li><i>rep</i> genes expression</li>
<li>genome <a href="/wiki/DNA_replication" title="DNA replication">replication</a></li>
<li><i>cap</i> genes expression, synthesis of progeny ssDNA particles</li>
<li>assembly of complete <a href="/wiki/Virion" title="Virion">virions</a>, and</li>
<li>release from the infected cell.</li>
</ol>
<p>Some of these steps may look different in various types of cells, which, in part, contributes to the defined and quite limited native tropism of AAV. Replication of the virus can also vary in one cell type, depending on the cell's current <a href="/wiki/Cell_cycle" title="Cell cycle">cell cycle</a> phase.<sup id="_ref-RohrKronenwett2002_0" class="reference"><a href="#_note-RohrKronenwett2002" title="">[57]</a></sup></p>
<p>The characteristic feature of the adeno-associated virus is a deficiency in replication and thus its inability to multiply in unaffected cells. The first factor that was described as providing successful generation of new AAV particles, was the <a href="/wiki/Adenovirus" title="Adenovirus">adenovirus</a>, from which the AAV name originated. It was then shown that AAV replication can be facilitated by selected proteins derived from the adenovirus genome,<sup id="_ref-MatsushitaElliger1998_0" class="reference"><a href="#_note-MatsushitaElliger1998" title="">[58]</a></sup><sup id="_ref-MyersLaughlin1980_0" class="reference"><a href="#_note-MyersLaughlin1980" title="">[59]</a></sup> by other viruses such as HSV,<sup id="_ref-HandaCarter1979_0" class="reference"><a href="#_note-HandaCarter1979" title="">[60]</a></sup> or by genotoxic agents, such as <a href="/wiki/UV" title="UV">UV</a> irradiation or <a href="/wiki/Hydroxyurea" title="Hydroxyurea">hydroxyurea</a>.<sup id="_ref-YalkinogluHeilbronn1988_0" class="reference"><a href="#_note-YalkinogluHeilbronn1988" title="">[61]</a></sup><sup id="_ref-YakobsonKoch1987_0" class="reference"><a href="#_note-YakobsonKoch1987" title="">[62]</a></sup><sup id="_ref-YakobsonHrynko1989_0" class="reference"><a href="#_note-YakobsonHrynko1989" title="">[63]</a></sup></p>
<p>The minimal set of the adenoviral genes required for efficient generation of progeny AAV particles, was discovered by Matsushita, Ellinger <i>et al</i>.<sup id="_ref-MatsushitaElliger1998_1" class="reference"><a href="#_note-MatsushitaElliger1998" title="">[58]</a></sup> This discovery allowed for new production methods of recombinant AAV, which do not require adenoviral co-infection of the AAV-producing cells. In the absence of helper virus or genotoxic factors, AAV DNA can either integrate into the host genome or persist in <a href="/wiki/Episome" title="Episome">episomal</a> form. In the former case integration is mediated by Rep78 and Rep68 proteins and requires the presence of ITRs flanking the region being integrated. In mice, the AAV genome has been observed persisting for long periods of time in quiescent tissues, such as skeletal muscles, in episomal form (a circular head-to-tail conformation).<sup id="_ref-DuanSharma1998_0" class="reference"><a href="#_note-DuanSharma1998" title="">[64]</a></sup></p>
<p><a name="Notes" id="Notes"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=19" title="Edit section: Notes">edit</a>]</span> <span class="mw-headline">Notes</span></h2>
<div style="height: 500px; overflow: auto;">
<div class="references-small" style="-moz-column-count:2; -webkit-column-count:2; column-count:2;">
<ol class="references">
<li id="_note-GriegerSamulski2005"><b><a href="#_ref-GriegerSamulski2005_0" title="">^</a></b> <cite id="CITEREFGriegerSamulski2005">Grieger, JC &amp; RJ Samulski (2005), written at <a href="/wiki/Berlin" title="Berlin">Berlin</a>, <a href="/wiki/Germany" title="Germany">Germany</a>, "Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications.", <i>Advances in biochemical engineering/biotechnology</i> (no. 99): 119-145</cite></li>
<li id="_note-SuroskyUrabe1997"><b><a href="#_ref-SuroskyUrabe1997_0" title="">^</a></b> <cite id="CITEREFSuroskyUrabeGodwin1997">Surosky, RT; M Urabe &amp; SG <i>et al</i> Godwin (1997), "Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome", <i>Journal of virology</i> <b>71</b>&#160;(10), <a href="http://www.ncbi.nlm.nih.gov/pubmed/9311886" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9311886">PMID 9311886</a></cite></li>
<li id="_note-ChirmulePropert1999"><b><a href="#_ref-ChirmulePropert1999_0" title="">^</a></b> <cite id="CITEREFChirmulePropertMagosin1999">Chirmule, N; K Propert &amp; S <i>et al</i> Magosin (1999), "Immune responses to adenovirus and adeno-associated virus in humans", <i>Gene therapy</i> (no. September): 1574-83, <a href="http://www.ncbi.nlm.nih.gov/pubmed/10490767" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10490767">PMID 10490767</a></cite></li>
<li id="_note-HernandezWang1999"><b><a href="#_ref-HernandezWang1999_0" title="">^</a></b> <cite id="CITEREFHernandezWangKearns1999">Hernandez, YJ; J Wang &amp; WG <i>et al</i> Kearns (1999), "Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model", <i>Journal of virology</i> (no. October): 8549-58, <a href="http://www.ncbi.nlm.nih.gov/pubmed/10482608" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10482608">PMID 10482608</a></cite></li>
<li id="_note-PonnazhaganMukherjee1997"><b><a href="#_ref-PonnazhaganMukherjee1997_0" title="">^</a></b> <cite id="CITEREFPonnazhaganMukherjeeYoder1997">Ponnazhagan, S; P Mukherjee &amp; MC <i>et al</i> Yoder (1997), "Adeno-associated virus 2-mediated gene transfer <i>in vivo</i>: organ-tropism and expression of transduced sequences in mice", <i>Gene</i> (no. Apr 29): 203-10, <a href="http://www.ncbi.nlm.nih.gov/pubmed/9185868" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9185868">PMID 9185868</a></cite></li>
<li id="_note-Carter2005">^ <a href="#_ref-Carter2005_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Carter2005_1" title=""><sup><i><b>b</b></i></sup></a> <cite id="CITEREFCarter2005">Carter, BJ (2005), "Adeno-Associated Virus Vectors in Clinical Trials", <i>Human Gene Therapy</i> <b>16</b>: 541-50, <a href="http://www.ncbi.nlm.nih.gov/pubmed/15916479" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15916479">PMID 15916479</a></cite></li>
<li id="_note-KaplittFeigin2007"><b><a href="#_ref-KaplittFeigin2007_0" title="">^</a></b> <cite id="CITEREFKaplittFeiginDuringothers2007">Kaplitt, MG; A Feigin &amp; MJ During et al. (2007), "Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial", <i>Lancet</i> <b>369</b>: 2097-2105, <a href="http://www.ncbi.nlm.nih.gov/pubmed/17586305" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17586305">PMID 17586305</a></cite></li>
<li id="_note-Carter2000"><b><a href="#_ref-Carter2000_0" title="">^</a></b> <cite id="CITEREFCarter2000">Carter, BJ (2000), "Adeno-associated virus and adeno-associated virus vectors for gene delivery", written at <a href="/wiki/New_York_City" title="New York City">New York City</a>, in DD Lassic &amp; N Smyth Templeton, <i>Gene Therapy: Therapeutic Mechanisms and Strategies</i>, Marcel Dekker, Inc., 41-59, <a href="/w/index.php?title=Special:Booksources&amp;isbn=0585395152" class="internal">ISBN 0-585-39515-2</a></cite></li>
<li id="_note-BohenzkyLefebvreBerns1988"><b><a href="#_ref-BohenzkyLefebvreBerns1988_0" title="">^</a></b> <cite id="CITEREFBohenzkyLeFebvreBerns1988">Bohenzky, RA; RB LeFebvre &amp; KI Berns (1988), written at <a href="/wiki/San_Diego" title="San Diego">San Diego</a>, "Sequence and symmetry requirements within the internal palindromic sequences of the adeno-associated virus terminal repeat", <i>Virology</i> (Academic Press) <b>166</b>&#160;(2), <a href="http://www.ncbi.nlm.nih.gov/pubmed/2845646" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2845646">PMID 2845646</a></cite></li>
<li id="_note-WangPonnazhagan1995"><b><a href="#_ref-WangPonnazhagan1995_0" title="">^</a></b> <cite id="CITEREFWangPonnazhaganSrivastava1995">Wang, X.S.; S. Ponnazhagan &amp; A Srivastava (1995), "Rescue and replication signals of the adeno-associated virus 2 genome", <i>Journal of Molecular Biology</i> <b>250</b>&#160;(5): 573-80, <a href="http://www.ncbi.nlm.nih.gov/pubmed/7623375" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/7623375">PMID 7623375</a></cite></li>
<li id="_note-WeitzmanKyostio1994">^ <a href="#_ref-WeitzmanKyostio1994_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-WeitzmanKyostio1994_1" title=""><sup><i><b>b</b></i></sup></a> <cite id="CITEREFWeitzmanKyostioKotinOwens1994">Weitzman, MD; SR Kyostio &amp; RM Kotin et al. (1994), "Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA", <i>Proceedings of the National Academy of Sciences of the United States of America</i> <b>91</b>&#160;(13): 5808-12, <a href="http://www.ncbi.nlm.nih.gov/pubmed/8016070" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/8016070">PMID 8016070</a></cite></li>
<li id="_note-ZhouMuzyczka1998"><b><a href="#_ref-ZhouMuzyczka1998_0" title="">^</a></b> <cite id="CITEREFZhouMuzyczka1998">Zhou, X &amp; N Muzyczka (1998), "In vitro packaging of adeno-associated virus DNA", <i>Journal of virology</i> <b>72</b>&#160;(4): 3241-7, <a href="http://www.ncbi.nlm.nih.gov/pubmed/9525651" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9525651">PMID 9525651</a></cite></li>
<li id="_note-NonyTessier2001"><b><a href="#_ref-NonyTessier2001_0" title="">^</a></b> <cite id="CITEREFNonyTessierChadeufWard2001">Nony, P; J Tessier &amp; G Chadeuf et al. (2001), "Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences", <i>Journal of virology</i> <b>75</b>&#160;(20): 9991-4, <a href="http://www.ncbi.nlm.nih.gov/pubmed/11559833" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11559833">PMID 11559833</a></cite></li>
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> <cite id="CITEREFNonyChadeufTessierMoullier2003">Nony, P; G Chadeuf &amp; J Tessier et al. (2003), "Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles", <i>Journal of virology</i> <b>77</b>&#160;(1), <a href="http://www.ncbi.nlm.nih.gov/pubmed/12477885" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12477885">PMID 12477885</a></cite></li>
<li id="_note-PhilpottGiraud2002"><b><a href="#_ref-PhilpottGiraud2002_0" title="">^</a></b> <cite id="CITEREFPhilpottGiraud-WaliDupuisGomos2002">Philpott, NJ; C Giraud-Wali &amp; C Dupuis et al. (2002), "Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis", <i>Journal of virology</i> <b>76</b>&#160;(11), <a href="http://www.ncbi.nlm.nih.gov/pubmed/11991970" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11991970">PMID 11991970</a></cite></li>
<li id="_note-1"><b><a href="#_ref-1" title="">^</a></b> <cite id="CITEREFTullisShenk2000">Tullis, GE &amp; T Shenk (2000), "Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size", <i>Journal of virology</i> <b>74</b>&#160;(24), <a href="http://www.ncbi.nlm.nih.gov/pubmed/11090148" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11090148">PMID 11090148</a></cite></li>
<li id="_note-KyostioOwens1994">^ <a href="#_ref-KyostioOwens1994_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-KyostioOwens1994_1" title=""><sup><i><b>b</b></i></sup></a> <cite id="CITEREFKyostioOwensWeitzmanAntoni1994">Kyostio, SR; RA Owens &amp; MD Weitzman et al. (1994), "Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels", <i>Journal of virology</i> <b>68</b>&#160;(5): 2947-57, <a href="http://www.ncbi.nlm.nih.gov/pubmed/8151765" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/8151765">PMID 8151765</a></cite></li>
<li id="_note-ImMuzyczka1990"><b><a href="#_ref-ImMuzyczka1990_0" title="">^</a></b> <cite id="CITEREFImMuzyczka1990">Im, DS &amp; N Muzyczka (1990), "The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity.", <i>Cell</i> <b>61</b>&#160;(3): 447-57, <a href="http://www.ncbi.nlm.nih.gov/pubmed/2159383" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2159383">PMID 2159383</a></cite></li>
<li id="_note-ImMuzyczka1992"><b><a href="#_ref-ImMuzyczka1992_0" title="">^</a></b> <cite id="CITEREFImMuzyczka1992">Im, DS &amp; N Muzyczka (1992), "Partial purification of adeno-associated virus Rep78, Rep52, and Rep40 and their biochemical characterization", <i>Journal of virology</i> <b>66</b>&#160;(2): 1119-28, <a href="http://www.ncbi.nlm.nih.gov/pubmed/1309894" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/1309894">PMID 1309894</a></cite></li>
<li id="_note-Samulski2003"><b><a href="#_ref-Samulski2003_0" title="">^</a></b> <cite id="CITEREFSamulski2003">Samulski, RJ (2003), "AAV vectors, the future workhorse of human gene therapy", <i>Ernst Schering Research Foundation workshop</i> (no. 43): 25-40, <a href="http://www.ncbi.nlm.nih.gov/pubmed/12894449" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12894449">PMID 12894449</a></cite></li>
<li id="_note-TrempeCarter1988a"><b><a href="#_ref-TrempeCarter1988a_0" title="">^</a></b> <cite id="CITEREFTrempeCarter1988a">Trempe, JP &amp; BJ Carter (1988a), "Regulation of adeno-associated virus gene expression in 293 cells: control of mRNA abundance and translation", <i>Journal of virology</i> (no. 1): 68-74, <a href="http://www.ncbi.nlm.nih.gov/pubmed/2824856" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2824856">PMID 2824856</a></cite></li>
<li id="_note-JayLaughlin1981"><b><a href="#_ref-JayLaughlin1981_0" title="">^</a></b> <cite id="CITEREFJayLaughlinCarter1981">Jay, FT; CA Laughlin &amp; BJ Carter (1981), "Eukaryotic translational control: adeno-associated virus protein synthesis is affected by a mutation in the adenovirus DNA-binding protein", <i>Proceedings of the National Academy of Sciences of the United States of America</i> <b>78</b>&#160;(5): 2927-31, <a href="http://www.ncbi.nlm.nih.gov/pubmed/6265925" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/6265925">PMID 6265925</a></cite></li>
<li id="_note-BecerraRose1985"><b><a href="#_ref-BecerraRose1985_0" title="">^</a></b> <cite id="CITEREFBecerraRoseHardyother1985">Becerra, SP; JA Rose &amp; M Hardy et al. (1985), "Direct mapping of adeno-associated virus capsid proteins B and C: a possible ACG initiation codon", <i>Proceedings of the National Academy of Sciences of the United States of America</i> <b>82</b>&#160;(23): 7919-23, <a href="http://www.ncbi.nlm.nih.gov/pubmed/2999784" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2999784">PMID 2999784</a></cite></li>
<li id="_note-CassinottiWeitz1988"><b><a href="#_ref-CassinottiWeitz1988_0" title="">^</a></b> <cite id="CITEREFCassinottiWeitzTratschin1988">Cassinotti, P; M Weitz &amp; JD Tratschin (1988), "Organization of the adeno-associated virus (AAV) capsid gene: mapping of a minor spliced mRNA coding for virus capsid protein 1", <i>Virology</i> <b>167</b>&#160;(1): 176-84, <a href="http://www.ncbi.nlm.nih.gov/pubmed/2847413" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2847413">PMID 2847413</a></cite></li>
<li id="_note-MuralidharBecerra1994">^ <a href="#_ref-MuralidharBecerra1994_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-MuralidharBecerra1994_1" title=""><sup><i><b>b</b></i></sup></a> <cite id="CITEREFMuralidharBecerraRose1994">Muralidhar, S; SP Becerra &amp; JA Rose (1994), "Site-directed mutagenesis of adeno-associated virus type 2 structural protein initiation codons: effects on regulation of synthesis and biological activity", <i>Journal of virology</i> <b>68</b>&#160;(1): 170-6, <a href="http://www.ncbi.nlm.nih.gov/pubmed/8254726" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/8254726">PMID 8254726</a></cite></li>
<li id="_note-TrempeCarter1988b"><b><a href="#_ref-TrempeCarter1988b_0" title="">^</a></b> <cite id="CITEREFTrempeCarter1988b">Trempe, JP &amp; BJ Carter (1988b), "Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein", <i>Journal of virology</i> <b>62</b>&#160;(9): 3356-63, <a href="http://www.ncbi.nlm.nih.gov/pubmed/2841488" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2841488">PMID 2841488</a></cite></li>
<li id="_note-RabinowitzSamulski2000"><b><a href="#_ref-RabinowitzSamulski2000_0" title="">^</a></b> <cite id="CITEREFRabinowitzSamulski2000">Rabinowitz, JE &amp; RJ Samulski (2000), "Building a better vector: the manipulation of AAV virions", <i>Virology</i> <b>278</b>&#160;(2): 301-8, <a href="http://www.ncbi.nlm.nih.gov/pubmed/11118354" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11118354">PMID 11118354</a></cite></li>
<li id="_note-GirodWobus2002"><b><a href="#_ref-GirodWobus2002_0" title="">^</a></b> <cite id="CITEREFGirodWobusZ.C3.A1doriothers2002">Girod, A; CE Wobus &amp; Z Zádori et al. (2002), "The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity", <i>The Journal of general virology</i> <b>83</b>&#160;(5): 973-8, <a href="http://www.ncbi.nlm.nih.gov/pubmed/11961250" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11961250">PMID 11961250</a></cite></li>
<li id="_note-WarringtonGorbatyuk1994"><b><a href="#_ref-WarringtonGorbatyuk1994_0" title="">^</a></b> <cite id="CITEREFWarringtonGorbatyukHarrisonothers2004">Warrington, KH,Jr; OS Gorbatyuk &amp; JK Harrison et al. (2004), "Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus", <i>Journal of virology</i> <b>78</b>&#160;(12): 6595-609, <a href="http://www.ncbi.nlm.nih.gov/pubmed/15163751" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15163751">PMID 15163751</a></cite></li>
<li id="_note-XieBu2002"><b><a href="#_ref-XieBu2002_0" title="">^</a></b> <cite id="CITEREFXieBuBhatiaothers2002">Xie, Q; W Bu &amp; S Bhatia et al. (2002), "The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy", <i>Proceedings of the National Academy of Sciences of the United States of America</i> <b>99</b>&#160;(16): 10405-10, <a href="http://www.ncbi.nlm.nih.gov/pubmed/12136130" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12136130">PMID 12136130</a></cite></li>
<li id="_note-MoriWang2004"><b><a href="#_ref-MoriWang2004_0" title="">^</a></b> <cite id="CITEREFMoriWangTakeuchiKanda2004">Mori, S; L Wang &amp; T Takeuchi et al. (2004), "Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein", <i>Virology</i> <b>330</b>&#160;(2): 375-83, <a href="http://www.ncbi.nlm.nih.gov/pubmed/15567432" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15567432">PMID 15567432</a></cite></li>
<li id="_note-BartlettSamulski1998">^ <a href="#_ref-BartlettSamulski1998_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-BartlettSamulski1998_1" title=""><sup><i><b>b</b></i></sup></a> <cite id="CITEREFBartlettSamulskiMcCownothers1998">Bartlett, JS; RJ Samulski &amp; TJ McCown et al. (1998), "Selective and rapid uptake of adeno-associated virus type 2 in brain", <i>Human gene therapy</i> <b>9</b>&#160;(8): 1181-6, <a href="http://www.ncbi.nlm.nih.gov/pubmed/9625257" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9625257">PMID 9625257</a></cite></li>
<li id="_note-FischerBeck2003"><b><a href="#_ref-FischerBeck2003_0" title="">^</a></b> <cite id="CITEREFFischerBeckSmithothers2003">Fischer, AC; SE Beck &amp; CI Smith et al. (2003), "Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques", <i>Molecular therapy&#160;: the journal of the <a href="/wiki/American_Society_of_Gene_Therapy" title="American Society of Gene Therapy">American Society of Gene Therapy</a></i> <b>8</b>&#160;(6): 918-26, <a href="http://www.ncbi.nlm.nih.gov/pubmed/14664794" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14664794">PMID 14664794</a></cite></li>
<li id="_note-NicklinBuening2001"><b><a href="#_ref-NicklinBuening2001_0" title="">^</a></b> <cite id="CITEREFNicklinBueningDishartothers2001">Nicklin, SA; H Buening &amp; KL Dishart et al. (2001), "Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells", <i>Molecular therapy&#160;: the journal of the American Society of Gene Therapy</i> <b>4</b>&#160;(3): 174-81, <a href="http://www.ncbi.nlm.nih.gov/pubmed/11545607" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11545607">PMID 11545607</a></cite></li>
<li id="_note-RabinowitzXiao1999"><b><a href="#_ref-RabinowitzXiao1999_0" title="">^</a></b> <cite id="CITEREFRabinowitzXiaoSamulski1999">Rabinowitz, JE; W Xiao &amp; RJ Samulski (1999), "Insertional mutagenesis of AAV2 capsid and the production of recombinant virus", <i>Virology</i> <b>265</b>&#160;(2): 274-85, <a href="http://www.ncbi.nlm.nih.gov/pubmed/10600599" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10600599">PMID 10600599</a></cite></li>
<li id="_note-ShiBartlett2003"><b><a href="#_ref-ShiBartlett2003_0" title="">^</a></b> <cite id="CITEREFShiBartlett2003">Shi, W &amp; JS Bartlett (2003), "RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism", <i>Molecular therapy&#160;: the journal of the American Society of Gene Therapy</i> <b>7</b>&#160;(4): 515-25, <a href="http://www.ncbi.nlm.nih.gov/pubmed/12727115" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12727115">PMID 12727115</a></cite></li>
<li id="_note-WuXiao2000"><b><a href="#_ref-WuXiao2000_0" title="">^</a></b> <cite id="CITEREFWuXiaoConlonothers2000">Wu, P; W Xiao &amp; T Conlon et al. (2000), "Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism", <i>Journal of virology</i> <b>74</b>&#160;(18): 8635-47, <a href="http://www.ncbi.nlm.nih.gov/pubmed/10954565" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10954565">PMID 10954565</a></cite></li>
<li id="_note-MannoChew2003"><b><a href="#_ref-MannoChew2003_0" title="">^</a></b> <cite id="CITEREFMannoChewHutchisonothers2003">Manno, CS; AJ Chew &amp; S Hutchison et al. (2003), "AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B", <i>Blood</i> <b>101</b>&#160;(8): 2963-72, <a href="http://www.ncbi.nlm.nih.gov/pubmed/12515715" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12515715">PMID 12515715</a></cite></li>
<li id="_note-RichterIwata2000"><b><a href="#_ref-RichterIwata2000_0" title="">^</a></b> <cite id="CITEREFRichterIwataNyhuisothers2000">Richter, M; A Iwata &amp; J Nyhuis et al. (2000), "Adeno-associated virus vector transduction of vascular smooth muscle cells <i>in vivo</i>", <i>Physiological genomics</i> <b>2</b>&#160;(3): 117-27, <a href="http://www.ncbi.nlm.nih.gov/pubmed/11015590" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11015590">PMID 11015590</a></cite></li>
<li id="_note-KoeberlAlexander1997"><b><a href="#_ref-KoeberlAlexander1997_0" title="">^</a></b> <cite id="CITEREFKoeberlAlexanderHalbertothers1997">Koeberl, DD; IE Alexander &amp; CL Halbert et al. (1997), "Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors", <i>Proceedings of the National Academy of Sciences of the United States of America</i> <b>94</b>&#160;(4): 1426-31, <a href="http://www.ncbi.nlm.nih.gov/pubmed/9037069" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9037069">PMID 9037069</a></cite></li>
<li id="_note-QinqMah1999"><b><a href="#_ref-QinqMah1999_0" title="">^</a></b> <cite id="CITEREFQingMahHansenother1999">Qing, K; C Mah &amp; J Hansen et al. (1999), "Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2", <i>Nature medicine</i> <b>5</b>&#160;(1): 71-7, <a href="http://www.ncbi.nlm.nih.gov/pubmed/9883842" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9883842">PMID 9883842</a></cite></li>
<li id="_note-SummerfordSamulski1998"><b><a href="#_ref-SummerfordSamulski1998_0" title="">^</a></b> <cite id="CITEREFSummerfordSamulski1998">Summerford, C &amp; RJ Samulski (1998), "Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions", <i>Journal of virology</i> <b>72</b>&#160;(2): 1438-45, <a href="http://www.ncbi.nlm.nih.gov/pubmed/9445046" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9445046">PMID 9445046</a></cite></li>
<li id="_note-SummerfordBartlett1999"><b><a href="#_ref-SummerfordBartlett1999_0" title="">^</a></b> <cite id="CITEREFSummerfordBartlettSamulski1999">Summerford, C; JS Bartlett &amp; RJ Samulski (1999), "AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection", <i>Nature medicine</i> <b>5</b>&#160;(1): 78-82, <a href="http://www.ncbi.nlm.nih.gov/pubmed/9883843" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9883843">PMID 9883843</a></cite></li>
<li id="_note-QiuHanda2001"><b><a href="#_ref-QiuHanda2001_0" title="">^</a></b> <cite id="CITEREFQiuHandaKirbyBrown2000">Qiu, J; A Handa &amp; M Kirby et al. (2000), "The interaction of heparin sulfate and adeno-associated virus 2", <i>Virology</i> <b>269</b>&#160;(1): 137-47, <a href="http://www.ncbi.nlm.nih.gov/pubmed/10725206" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10725206">PMID 10725206</a></cite></li>
<li id="_note-PajusolaGruchala2002"><b><a href="#_ref-PajusolaGruchala2002_0" title="">^</a></b> <cite id="CITEREFPajusolaGruchalaJochother2002">Pajusola, K; M Gruchala &amp; H Joch et al. (2002), "Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells", <i>Journal of virology</i> <b>76</b>&#160;(22): 11530-40, <a href="http://www.ncbi.nlm.nih.gov/pubmed/12388714" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12388714">PMID 12388714</a></cite></li>
<li id="_note-Cnn2005"><b><a href="#_ref-Cnn2005_0" title="">^</a></b> <cite id="CITEREFCNN.com2005">CNN.com (2005), <i><a href="http://www.cnn.com/2005/HEALTH/06/22/cancer.virus/index.html" class="external text" title="http://www.cnn.com/2005/HEALTH/06/22/cancer.virus/index.html" rel="nofollow">Common virus 'kills cancer'</a></i><span class="printonly">, &lt;<a href="http://www.cnn.com/2005/HEALTH/06/22/cancer.virus/index.html" class="external free" title="http://www.cnn.com/2005/HEALTH/06/22/cancer.virus/index.html" rel="nofollow">http://www.cnn.com/2005/HEALTH/06/22/cancer.virus/index.html</a>&gt;</span>. Retrieved on August 23, 2006</cite></li>
<li id="_note-GaoAlvira2002"><b><a href="#_ref-GaoAlvira2002_0" title="">^</a></b> <cite id="CITEREFGaoAlviraWangother2002">Gao, GP; MR Alvira &amp; L Wang et al. (2002), <i>Proceedings of the National Academy of Sciences of the United States of America</i> <b>99</b>&#160;(18): 11854-9, <a href="http://www.ncbi.nlm.nih.gov/pubmed/12192090" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12192090">PMID 12192090</a></cite></li>
<li id="_note-HalbertAllen2001">^ <a href="#_ref-HalbertAllen2001_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-HalbertAllen2001_1" title=""><sup><i><b>b</b></i></sup></a> <cite id="CITEREFHalbertAllenMiller2001">Halbert, CL; JM Allen &amp; AD Miller (2001), "Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors", <i>Journal of virology. (J Virol) Jul; ():</i> <b>75</b>&#160;(14): 6615-24, <a href="http://www.ncbi.nlm.nih.gov/pubmed/11413329" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11413329">PMID 11413329</a></cite></li>
<li id="_note-RabinowitzBowles2004">^ <a href="#_ref-RabinowitzBowles2004_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-RabinowitzBowles2004_1" title=""><sup><i><b>b</b></i></sup></a> <cite id="CITEREFRabinowitzBowlesFaustother2004">Rabinowitz, JE; DE Bowles &amp; SM Faust et al. (2004), "Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups", <i>Journal of virology</i> <b>78</b>&#160;(9): 4421-32, <a href="http://www.ncbi.nlm.nih.gov/pubmed/15078923" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15078923">PMID 15078923</a></cite></li>
<li id="_note-ChenKapturczak2005"><b><a href="#_ref-ChenKapturczak2005_0" title="">^</a></b> <cite id="CITEREFChenKapturczakLoilerothers2005">Chen, S; M Kapturczak &amp; SA Loiler et al. (2005), "Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors", <i>Human gene therapy</i> <b>16</b>&#160;(2): 235-47, <a href="http://www.ncbi.nlm.nih.gov/pubmed/15761263" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15761263">PMID 15761263</a></cite></li>
<li id="_note-KaludovBrown2001"><b><a href="#_ref-KaludovBrown2001_0" title="">^</a></b> <cite id="CITEREFKaludovBrownWaltersothers2001">Kaludov, N; KE Brown &amp; RW Walters et al. (2001), "Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity", <i>Journal of virology</i> <b>75</b>&#160;(15): 6884-93, <a href="http://www.ncbi.nlm.nih.gov/pubmed/11435568" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11435568">PMID 11435568</a></cite></li>
<li id="_note-DiPasqualeDavidson2003"><b><a href="#_ref-DiPasqualeDavidson2003_0" title="">^</a></b> <cite id="CITEREFDi_PasqualeDavidsonSteinothers">Di Pasquale, G; BL Davidson &amp; CS Stein et al., "Identification of PDGFR as a receptor for AAV-5 transduction", <i>Nature medicine</i> <b>9</b>&#160;(10): 1306-12, <a href="http://www.ncbi.nlm.nih.gov/pubmed/14502277" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14502277">PMID 14502277</a></cite></li>
<li id="_note-ZaissLiu2002"><b><a href="#_ref-ZaissLiu2002_0" title="">^</a></b> <cite id="CITEREFZaissLiuBowenothers2002">Zaiss, AK; Q Liu &amp; GP Bowen et al. (2002), "Differential Activation of Innate Immune Responses by Adenovirus and Adeno-Associated Virus Vectors", <i>Journal of Virology</i> <b>76</b>&#160;(9): 4580-90, <a href="http://www.ncbi.nlm.nih.gov/pubmed/11932423" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11932423">PMID 11932423</a></cite></li>
<li id="_note-ZaissMuruve2005">^ <a href="#_ref-ZaissMuruve2005_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-ZaissMuruve2005_1" title=""><sup><i><b>b</b></i></sup></a> <cite id="CITEREFZaissMuruve2005">Zaiss, AK &amp; DA Muruve (2005), "Immune responses to adeno-associated virus vectors", <i>Current Gene Therapy</i> <b>5</b>&#160;(3): 323-31, <a href="http://www.ncbi.nlm.nih.gov/pubmed/15975009" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15975009">PMID 15975009</a></cite></li>
<li id="_note-MannosHigh2006"><b><a href="#_ref-MannosHigh2006_0" title="">^</a></b> <cite id="CITEREFHighMannosPierceOthers2006">High, KA; CS Mannos &amp; GF Pierce et al. (2006), "Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response", <i>Nature Medicine</i> <b>12</b>&#160;(3): 342-47, <a href="http://www.ncbi.nlm.nih.gov/pubmed/16474400" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16474400">PMID 16474400</a></cite></li>
<li id="_note-SabatinoHigh2005"><b><a href="#_ref-SabatinoHigh2005_0" title="">^</a></b> <cite id="CITEREFHighSabatinoMingozziOthers2005">High, KA; DE Sabatino &amp; F Mingozzi et al. (2005), "Identification of Mouse AAV Capsid-Specific CD8+ T Cell Epitopes", <i>Molecular Therapy</i> <b>12</b>&#160;(6): 1023-33, <a href="http://www.ncbi.nlm.nih.gov/pubmed/16263332" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16263332">PMID 16263332</a></cite></li>
<li id="_note-RohrKronenwett2002"><b><a href="#_ref-RohrKronenwett2002_0" title="">^</a></b> <cite id="CITEREFRohrKronenwettGrimmothers2002">Rohr, UP; R Kronenwett &amp; D Grimm et al. (2002), "Primary human cells differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression", <i>Journal of virological methods</i> <b>105</b>&#160;(2): 265-75, <a href="http://www.ncbi.nlm.nih.gov/pubmed/12270659" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12270659">PMID 12270659</a></cite></li>
<li id="_note-MatsushitaElliger1998">^ <a href="#_ref-MatsushitaElliger1998_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-MatsushitaElliger1998_1" title=""><sup><i><b>b</b></i></sup></a> <cite id="CITEREFMatsushitaElligerElligerothers1998">Matsushita, T; S Elliger &amp; C Elliger et al. (1998), "Adeno-associated virus vectors can be efficiently produced without helper virus", <i>Gene therapy</i> <b>5</b>&#160;(7): 938-45, <a href="http://www.ncbi.nlm.nih.gov/pubmed/9813665" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9813665">PMID 9813665</a></cite></li>
<li id="_note-MyersLaughlin1980"><b><a href="#_ref-MyersLaughlin1980_0" title="">^</a></b> <cite id="CITEREFMyersLaughlinJayother1980">Myers, MW; CA Laughlin &amp; FT Jay et al. (1980), "Adenovirus helper function for growth of adeno-associated virus: effect of temperature-sensitive mutations in adenovirus early gene region 2", <i>Journal of virology</i> <b>35</b>&#160;(1): 65-75, <a href="http://www.ncbi.nlm.nih.gov/pubmed/6251278" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/6251278">PMID 6251278</a></cite></li>
<li id="_note-HandaCarter1979"><b><a href="#_ref-HandaCarter1979_0" title="">^</a></b> <cite id="CITEREFHandaCarter1979">Handa, H &amp; BJ Carter (1979), "Adeno-associated virus DNA replication complexes in herpes simplex virus or adenovirus-infected cells", <i>The Journal of biological chemistry</i> <b>254</b>&#160;(14): 6603-10, <a href="http://www.ncbi.nlm.nih.gov/pubmed/221504" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/221504">PMID 221504</a></cite></li>
<li id="_note-YalkinogluHeilbronn1988"><b><a href="#_ref-YalkinogluHeilbronn1988_0" title="">^</a></b> <cite id="CITEREFYalkinogluHeilbronnB.C3.BCrkleother1988">Yalkinoglu, AO; R Heilbronn &amp; A Bürkle et al. (1988), "DNA amplification of adeno-associated virus as a response to cellular genotoxic stress", <i>Cancer research</i> <b>48</b>&#160;(11): 3123-9, <a href="http://www.ncbi.nlm.nih.gov/pubmed/2835153" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2835153">PMID 2835153</a></cite></li>
<li id="_note-YakobsonKoch1987"><b><a href="#_ref-YakobsonKoch1987_0" title="">^</a></b> <cite id="CITEREFYakobsonKochWinocour1987">Yakobson, B; T Koch &amp; E Winocour (1987), "Replication of adeno-associated virus in synchronized cells without the addition of a helper virus", <i>Journal of virology</i> <b>61</b>&#160;(4): 972-81, <a href="http://www.ncbi.nlm.nih.gov/pubmed/3029431" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/3029431">PMID 3029431</a></cite></li>
<li id="_note-YakobsonHrynko1989"><b><a href="#_ref-YakobsonHrynko1989_0" title="">^</a></b> <cite id="CITEREFYakobsonHrynkoPeakWinocour1989">Yakobson, B; TA Hrynko &amp; MJ Peak et al. (1989), "Replication of adeno-associated virus in cells irradiated with UV light at 254 nm", <i>Journal of virology</i> <b>63</b>&#160;(3): 1023-30, <a href="http://www.ncbi.nlm.nih.gov/pubmed/2536816" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2536816">PMID 2536816</a></cite></li>
<li id="_note-DuanSharma1998"><b><a href="#_ref-DuanSharma1998_0" title="">^</a></b> <cite id="CITEREFDuanSharmaYangothers1998">Duan, D; P Sharma &amp; J Yang et al. (1998), "Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue", <i>Journal of virology</i> <b>72</b>&#160;(11): 8568-77, <a href="http://www.ncbi.nlm.nih.gov/pubmed/9765395" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9765395">PMID 9765395</a></cite></li>
</ol>
</div>
</div>
<p><br /></p>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit&amp;section=20" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/G/GeneTherapy2.html" class="external free" title="http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/G/GeneTherapy2.html" rel="nofollow">http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/G/GeneTherapy2.html</a></li>
<li><a href="http://www.genetherapynet.com" class="external text" title="http://www.genetherapynet.com" rel="nofollow">Gene Therapy Net</a></li>
</ul>


<!-- 
NewPP limit report
Preprocessor node count: 20472/1000000
Post-expand include size: 137450/2048000 bytes
Template argument size: 48007/2048000 bytes
#ifexist count: 0/500
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:1883421-0!1!0!default!!en!2 and timestamp 20080124110458 -->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org/wiki/Adeno-associated_virus">http://en.wikipedia.org/wiki/Adeno-associated_virus</a>"</div>
			<div id="catlinks"><p class='catlinks'><a href="/wiki/Special:Categories" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="/wiki/Category:Articles_to_be_expanded_since_January_2007" title="Category:Articles to be expanded since January 2007">Articles to be expanded since January 2007</a></span> | <span dir='ltr'><a href="/wiki/Category:All_articles_to_be_expanded" title="Category:All articles to be expanded">All articles to be expanded</a></span> | <span dir='ltr'><a href="/wiki/Category:Applied_genetics" title="Category:Applied genetics">Applied genetics</a></span> | <span dir='ltr'><a href="/wiki/Category:Oncology" title="Category:Oncology">Oncology</a></span> | <span dir='ltr'><a href="/wiki/Category:Viruses" title="Category:Viruses">Viruses</a></span></p></div>			<!-- end content -->
			<div class="visualClear"></div>
		</div>
	</div>
		</div>
		<div id="column-one">
	<div id="p-cactions" class="portlet">
		<h5>Views</h5>
		<div class="pBody">
			<ul>
					 <li id="ca-nstab-main" class="selected"><a href="/wiki/Adeno-associated_virus" title="View the content page [c]" accesskey="c">Article</a></li>
					 <li id="ca-talk"><a href="/wiki/Talk:Adeno-associated_virus" title="Discussion about the content page [t]" accesskey="t">Discussion</a></li>
					 <li id="ca-edit"><a href="/w/index.php?title=Adeno-associated_virus&amp;action=edit" title="You can edit this page. Please use the preview button before saving. [e]" accesskey="e">Edit this page</a></li>
					 <li id="ca-history"><a href="/w/index.php?title=Adeno-associated_virus&amp;action=history" title="Past versions of this page [h]" accesskey="h">History</a></li>
					 <li id="ca-move"><a href="/wiki/Special:Movepage/Adeno-associated_virus" title="Rename this page [m]" accesskey="m">Move</a></li>
					 <li id="ca-watch"><a href="/w/index.php?title=Adeno-associated_virus&amp;action=watch" title="Add this page to your watchlist [w]" accesskey="w">Watch</a></li>
				</ul>
		</div>
	</div>
	<div class="portlet" id="p-personal">
		<h5>Personal tools</h5>
		<div class="pBody">
			<ul>
				<li id="pt-userpage"><a href="/wiki/User:Kanzure" title="My user page [.]" accesskey=".">Kanzure</a></li>
				<li id="pt-mytalk"><a href="/wiki/User_talk:Kanzure" title="My talk page [n]" accesskey="n">My talk</a></li>
				<li id="pt-preferences"><a href="/wiki/Special:Preferences" title="My preferences">My preferences</a></li>
				<li id="pt-watchlist"><a href="/wiki/Special:Watchlist" title="The list of pages that you are monitoring for changes [l]" accesskey="l">My watchlist</a></li>
				<li id="pt-mycontris"><a href="/wiki/Special:Contributions/Kanzure" title="List of my contributions [y]" accesskey="y">My contributions</a></li>
				<li id="pt-logout"><a href="/w/index.php?title=Special:Userlogout&amp;returnto=Adeno-associated_virus" title="Log out">Log out</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-logo">
		<a style="background-image: url(/images/wiki-en.png);" href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
		<h5>Navigation</h5>
		<div class='pBody'>
			<ul>
				<li id="n-mainpage"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main Page</a></li>
				<li id="n-Contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li>
				<li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content">Featured content</a></li>
				<li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li>
				<li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li>
			</ul>
		</div>
	</div>
		<div class='portlet' id='p-interaction'>
		<h5>Interaction</h5>
		<div class='pBody'>
			<ul>
				<li id="n-About-Wikipedia"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li>
				<li id="n-portal"><a href="/wiki/Wikipedia:Community_Portal" title="About the project, what you can do, where to find things">Community portal</a></li>
				<li id="n-recentchanges"><a href="/wiki/Special:Recentchanges" title="The list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li>
				<li id="n-contact"><a href="/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact Wikipedia</a></li>
				<li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Donate" title="Support us">Donate to Wikipedia</a></li>
				<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li>
			</ul>
		</div>
	</div>
		<div id="p-search" class="portlet">
		<h5><label for="searchInput">Search</label></h5>
		<div id="searchBody" class="pBody">
			<form action="/wiki/Special:Search" id="searchform"><div>
				<input id="searchInput" name="search" type="text" title="Search Wikipedia [f]" accesskey="f" value="" />
				<input type='submit' name="go" class="searchButton" id="searchGoButton"	value="Go" title="Go to a page with this exact name if one exists" />&nbsp;
				<input type='submit' name="fulltext" class="searchButton" id="mw-searchButton" value="Search" title="Search the wiki for this text" />
			</div></form>
		</div>
	</div>
	<div class="portlet" id="p-tb">
		<h5>Toolbox</h5>
		<div class="pBody">
			<ul>
				<li id="t-whatlinkshere"><a href="/wiki/Special:Whatlinkshere/Adeno-associated_virus" title="List of all English Wikipedia pages that link here [j]" accesskey="j">What links here</a></li>
				<li id="t-recentchangeslinked"><a href="/wiki/Special:Recentchangeslinked/Adeno-associated_virus" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li>
<li id="t-upload"><a href="/wiki/Wikipedia:Upload" title="Upload images or media files [u]" accesskey="u">Upload file</a></li>
<li id="t-specialpages"><a href="/wiki/Special:Specialpages" title="List of all special pages [q]" accesskey="q">Special pages</a></li>
				<li id="t-print"><a href="/w/index.php?title=Adeno-associated_virus&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>				<li id="t-permalink"><a href="/w/index.php?title=Adeno-associated_virus&amp;oldid=181932463" title="Permanent link to this version of the page">Permanent link</a></li><li id="t-cite"><a href="/w/index.php?title=Special:Cite&amp;page=Adeno-associated_virus&amp;id=181932463">Cite this page</a></li>			</ul>
		</div>
	</div>
	<div id="p-lang" class="portlet">
		<h5>Languages</h5>
		<div class="pBody">
			<ul>
				<li class="interwiki-de"><a href="http://de.wikipedia.org/wiki/Adeno-assoziierte_Viren">Deutsch</a></li>
				<li class="interwiki-it"><a href="http://it.wikipedia.org/wiki/Virus_adeno-associati">Italiano</a></li>
			</ul>
		</div>
	</div>
		</div><!-- end of the left (by default at least) column -->
			<div class="visualClear"></div>
			<div id="footer">
				<div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="/skins-1.5/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>
				<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="/images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>
			<ul id="f-list">
				<li id="lastmod"> This page was last modified 19:30, 3 January 2008.</li>
				<li id="copyright">All text is available under the terms of the <a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Copyrights" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a U.S. registered <a class='internal' href="http://en.wikipedia.org/wiki/501%28c%29#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="http://en.wikipedia.org/wiki/Non-profit_organization" title="Non-profit organization">nonprofit</a> <a href="http://en.wikipedia.org/wiki/Charitable_organization" title="Charitable organization">charity</a>.<br /></li>
				<li id="privacy"><a href="http://wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
				<li id="about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
				<li id="disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
			</ul>
		</div>
		
	
		<script type="text/javascript">if (window.runOnloadHook) runOnloadHook();</script>
</div>
<!-- Served by srv107 in 0.060 secs. --></body></html>
